519 related articles for article (PubMed ID: 11277616)
1. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
2. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.
Sun Q; Burton RL; Pollok KE; Emanuel DJ; Lucas KG
Cell Immunol; 1999 Aug; 195(2):81-8. PubMed ID: 10448007
[TBL] [Abstract][Full Text] [Related]
3. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I
Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731
[TBL] [Abstract][Full Text] [Related]
5. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
6. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
7. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
8. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of IL-7 and IL-12 on human T cell activation.
Mehrotra PT; Grant AJ; Siegel JP
J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
Konttinen YT; Bluestein HG; Zvaifler NJ
J Immunol; 1985 Apr; 134(4):2287-93. PubMed ID: 2857749
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
12. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.
Guppy AE; Rawlings E; Madrigal JA; Amlot PL; Barber LD
Transplantation; 2007 Dec; 84(11):1534-9. PubMed ID: 18091531
[TBL] [Abstract][Full Text] [Related]
13. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells.
Khanolkar A; Yagita H; Cannon MJ
Virology; 2001 Aug; 287(1):79-88. PubMed ID: 11504544
[TBL] [Abstract][Full Text] [Related]
14. Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient.
Piriou ER; van Dort K; Weel JF; Bemelman FJ; Gamadia LE; van Oers MH; van Baarle D
Clin Immunol; 2006 Apr; 119(1):16-20. PubMed ID: 16386961
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
16. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
18. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy.
Feuchtinger T; Lang P; Hamprecht K; Schumm M; Greil J; Jahn G; Niethammer D; Einsele H
Exp Hematol; 2004 Mar; 32(3):282-9. PubMed ID: 15003314
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive phenotypic analysis of the gut intra-epithelial lymphocyte compartment: perturbations induced by acute reovirus 1/L infection of the gastrointestinal tract.
Bharhani MS; Grewal JS; Peppler R; Enockson C; London L; London SD
Int Immunol; 2007 Apr; 19(4):567-79. PubMed ID: 17369189
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus (EBV)-induced long-term proliferation of CD4+ lymphocytes leading to T lymphoblastoid cell lines carrying EBV.
Guan M; Romano G; Henderson EE
Anticancer Res; 1999; 19(4B):3007-17. PubMed ID: 10652585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]